For example, MET reduced the development of T2DM by 31% in the US Diabetes Prevention Program study, presumably through its indirect effects to reduce β-cell workload (inhibition of hepatic glucose production and improved hepatic insulin sensitivity). Here, INS is linked to type 2 diabetes mellitus.